### 2025-06-19 Advancing research on regulatory autoantibodies targeting GPCRs: Insights from the 5th international symposium

- **Metadata:**
    - **Authors:** Cabral-Marques, Otavio; Schimke, Lena F.; Moll, Guido.
    - **Institutes:** Laboratory of Psychoneuroimmunology, Selye Lab, University of SÃ£o Paulo School of Medicine, SÃ£o Paulo, Brazil; Department of Medicine, Division of Molecular Medicine, Laboratory of Medical Investigation 29, University of SÃ£o Paulo School of Medicine, SÃ£o Paulo, Brazil; Network of Immunity in Infection, Malignancy, and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Sao Paulo, Brazil.
    - **Publisher:** Autoimmunity Reviews
    - **Link:** [DOI](https://doi.org/10.1016/j.autrev.2025.103855)
- **What was researched?**
This paper summarizes the key findings from the 5th International Symposium on Regulatory Autoantibodies Targeting G-protein-coupled receptors (RAB-GPCRs). It reviews the current understanding of how these autoantibodies function as active modulators in various diseases, including Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and Post-COVID Syndrome (PCS), and explores their potential as biomarkers and therapeutic targets.
- **Why was it researched?**
This research was motivated by the growing evidence that autoantibodies targeting GPCRs are not merely passive disease markers but are active contributors to pathophysiology by altering cellular signaling. The symposium aimed to bring together experts from immunology, neurology, and rheumatology to consolidate knowledge and address the complex role these autoantibodies play in post-viral illnesses like ME/CFS/PCS and other autoimmune conditions.
- **How was it researched?**
This article is a comprehensive review and summary report of the scientific presentations and discussions from an international symposium. It synthesizes findings from recent studies and expert consensus across multiple fields. A key area of focus was a recent study by Hoheisel et al., which investigated the role of Epstein-Barr Virus (EBV) in triggering the production of these autoantibodies in ME/CFS and PCS patients.
- **What has been found?**
The symposium reinforced that functionally active autoantibodies targeting GPCRs are significantly involved in ME/CFS and PCS pathophysiology. A major insight discussed was that Epstein-Barr Virus (EBV) reactivation may be a key trigger, as certain EBV proteins mimic human GPCRs, leading to cross-reactive autoantibodies through molecular mimicry. These autoantibodies were found to be elevated in ME/CFS and PCS patients, correlated with symptom severity, and are believed to contribute directly to symptoms like dysautonomia, fatigue, and pain by disrupting adrenergic receptor signaling. The paper also noted that pathological effects of certain GPCR autoantibodies on blood vessel lining could be reversed by losartan ðŸ’Š in a laboratory setting.
- **Discussion:**
The authors highlight a paradigm shift in understanding anti-GPCR autoantibodies, now viewing them as dynamic, functionally active agents rather than static biomarkers. They note that these autoantibodies can have a dual nature, acting as either regulatory or pathogenic depending on their concentration, specificity, and the biological context. A primary challenge that remains is to distinguish between their normal regulatory functions and their disease-causing roles to develop them into reliable clinical tools.
- **Conclusion & Future Work:**
The authors conclude that autoantibodies targeting GPCRs are central players in the mechanisms of a wide spectrum of diseases, including ME/CFS. They strongly advocate for future research to adopt integrative, systems-level approaches that combine autoantibody profiles with other biological data (multi-omics). Such approaches are considered essential for decoding the full impact of these autoantibodies and developing novel strategies for diagnosis and precision immunomodulation in chronic diseases.
- **Summary:**
This report consolidates strong evidence that functional autoantibodies attacking the body's own cellular receptors (GPCRs) are a key part of the disease process in ME/CFS and post-COVID conditions. It highlights a compelling theory that Epstein-Barr Virus (EBV) reactivation can trigger the production of these harmful autoantibodies through "molecular mimicry," offering a potential explanation for the autoimmune features of the illness. This mechanism provides a direct biological basis for symptoms like autonomic dysfunction and fatigue, as these autoantibodies can disrupt critical signaling pathways. This line of research is crucial as it paves the way for specific diagnostic markers and targeted treatments aimed at removing or blocking these autoantibodies.
- **Simple Summary:**
Scientists are increasingly certain that in ME/CFS, the immune system mistakenly creates antibodies that attack the body's own cell receptors. New findings suggest that the Epstein-Barr virus (EBV) may trigger this process by tricking the immune system. This understanding helps explain symptoms and is guiding research toward new diagnostic tests and targeted treatments.
